@article {Petkovicjrheum.160975, author = {Jennifer Petkovic and Jennifer L. Barton and Caroline Flurey and Niti Goel and Christie M. Bartels and Cheryl Barnabe and Maarten P.T. de Wit and Anne Lyddiatt and Diane Lacaille and Vivian Welch and Annelies Boonen and Beverley Shea and Robin Christensen and Lara J. Maxwell and Willemina Campbell and Janet Jull and Karine Toupin-April and Jasvinder A. Singh and Charles H. Goldsmith and Antoine G. Sreih and Christoph Pohl and Catherine Hofstetter and Dorcas E. Beaton and Rachelle Buchbinder and Francis Guillemin and Peter S. Tugwell}, title = {Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group}, elocation-id = {jrheum.160975}, year = {2017}, doi = {10.3899/jrheum.160975}, publisher = {The Journal of Rheumatology}, abstract = {Objective Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether and how to address equity issues within the core outcome sets of domains and instruments. Methods We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients. At OMERACT 2016, results of the survey and a narrative review of differential psychosocial effects of rheumatoid arthritis (i.e., on men) were presented to stimulate discussion and develop a research agenda. Results We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM): (1) recruitment, (2) domain selection, (3) feasibility in diverse settings, (4) instrument validity, (5) thresholds of meaning, and (6) consideration of statistical power of subgroup analyses for outcome reporting. Conclusion There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient{\textquoteright}s response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/early/2017/02/09/jrheum.160975}, eprint = {https://www.jrheum.org/content/early/2017/02/09/jrheum.160975.full.pdf}, journal = {The Journal of Rheumatology} }